Evidence map›Paper›PMID 30384842›Full record

Trial reportCardiovascular diabetology2018

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.

Guillaume Besch, Andrea Perrotti, Lucie Salomon du Mont, Marc Puyraveau, Xavier Ben-Said, Maude Baltres, Benoit Barrucand, Guillaume Flicoteaux, Lucie Vettoretti, Emmanuel Samain and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969149 (Intravenous Exenatide), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969149 phase2 / phase3completednot on this map

Intravenous Exenatide (Byetta®) Versus Insulin for Perioperative Glycemic Control in Cardiac Surgery: the Open-labeled Randomized Phase II/III ExStress Study

TypeinterventionalSponsorCentre Hospitalier Universitaire de BesanconRan2015 to 2016Enrolled110ConditionsStress HyperglycemiaArmsExenatide, Insulin
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Glucose-lowering therapy in patients undergoing percutaneous coronary intervention.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Guillaume BeschDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France. gbesch@chu-besancon.fr.
Andrea PerrottiDepartment of Cardiothoracic Surgery, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Lucie Salomon du MontDepartment of Vascular Surgery, University Hospital of Besancon, and, EA3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Marc PuyraveauClinical Methodology Center, University Hospital of Besancon, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Xavier Ben-SaidDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Maude BaltresDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Benoit BarrucandDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Guillaume FlicoteauxDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Lucie VettorettiDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Emmanuel SamainDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Sidney ChocronDepartment of Cardiothoracic Surgery, University Hospital of Besancon, and, EA3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Sebastien Pili-FlouryDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.
Université de franche-comté · FRInserm · FR

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe aim of the study was to investigate whether intravenous (iv) infusion of exenatide, a synthetic GLP-1 receptor agonist, could provide a protective effect against myocardial ischemia-reperfusion injury after coronary artery bypass graft (CABG) surgery.

methodsA sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted. Patients were randomized to receive either iv exenatide (1-h bolus of 0.05 µg min

resultsFinally, 43 and 49 patients were analyzed in the control and exenatide groups, respectively {age: 69 [61-76] versus 71 [63-75] years; baseline LVEF < 50%: 6 (14%) versus 16 (32%) patients; on-pump surgery: 29 (67%) versus 33 (67%) patients}. The primary outcome did not significantly differ between the two groups (3.34 [1.06-6.19] µg l

conclusionsPostoperative iv exenatide did not provide any additional cardioprotective effect compared to iv insulin in low-risk patients undergoing scheduled CABG surgery. Trial registration ClinicalTrials.gov Identifier NCT01969149, date of registration: January 7th, 2015; EudraCT No. 2009-009254-25 A, date of registration: January 6th, 2009.

Indexed as

AgedBiomarkersBlood GlucoseCoronary Artery BypassExenatideFemaleFranceHumansHypoglycemic AgentsIncretinsInfusions, IntravenousMaleMiddle AgedMyocardial Reperfusion InjuryRisk FactorsStroke VolumeBiomarkersBlood GlucoseExenatideHypoglycemic AgentsIncretinsTroponin ICardioprotective effectsCoronary artery bypassExenatideGlucagon-like peptide 1IncretinsMyocardial reperfusion injury

Identifiers

PMID30384842
PMCPMC6211400
OpenAlexW2899380388

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.